Run-Ling Wang, Professor
发布人：药学院-英文  发布时间：2022-04-27   浏览次数:232

 


Run-Ling Wang, Ph.D.

 


Run-Ling Wang, PhD

Professor 

School of pharmacy

Tianjin Medical University 

22 Qixiangtai Road

Tianjin 300070

Phone: 86-13602030967

Email: wangrunling@tmu.edu.cn

 

Education

BSc.      Medicinal Chemistry, Peking University Health Science Center, Beijing, China, 1978-1982

Ph.D.     Applied Chemistry, Tianjin University, Tianjin, China,2003-2006

 

Professional Experience

1994-1999    Associate Professor, Department of Pharmacy, Tianjin Medical University, Tianjin, China

1999-            Professor, Department of Pharmacy, Tianjin Medical University, Tianjin, China

2001-2002    Senior visiting scholar of Uppsala University, Sweden


Research Interest

Computer aided drug design, synthesis and activity screening


Honors

The third prize of Tianjin science and technology progress, 2003;

6 invention patents；

Tianjin excellent teachers, 2009;

The second prize of teaching achievement of Tianjin educational reform project 2009；

Editor in chief of 3 teaching textbooks, joined in editing 4 teaching textbooks.


Professional Service

A member of Chinese medicine institute of pharmaceutical chemistry committee;

Deputy director of medicinal chemistry council in Tianjin;

Tianjin new drug review experts.


Membership of Academic Society

Tianjin Pharmaceutical Association

Tianjin Key Laboratory of Modern Drug Delivery and Functional Efficiency

Tianjin Key Laboratory of Molecular Design and Drug Discovery

 

  

Selected Publications


  1. Ma Yangchun, Yang WenYu, Zhou Liang, Li LiPeng, Wu JingWei, Li WeiYa, Du Shan, Ma Ying* & Wang RunLing*. Exploring the cause of the dual allosteric targeted inhibition attaching to allosteric sites enhancing SHP2 inhibition. [J]. Molecular Diversity, 2021. Doi: 10.1007/s11030-021-10286-4.

  2. Hao-Xin Li, Wen-Yu Yang, Li-Peng Li, Hui Zhou, Wei-Ya Li, Ying Ma*, Run-Ling Wang*. Molecular dynamics study of CDC25BR492L mutant causing the activity decrease of CDC25B. [J]. Journal of Molecular Graphics and Modelling. 2021; 109: 108030. Doi: 10.1016/j.jmgm.2021.108030.

  3. Shan Du, Xin-hua Lu, Wei-Ya Li, Li-Peng Li, Yang-Chun Ma, Liang Zhou, Jing-Wei Wu, Ying Ma* & Run-Ling Wang*. Exploring the dynamic mechanism of allosteric drug SHP099 inhibiting SHP2E69K. [J]. Molecular Diversity. 2021; 25, 1873–1887. Doi: 10.1007/s11030-020-10179-y.

  4. Ying-Zhan Sun, Jing-Wei Wu, Shan Du, Yang-Chun Ma, Liang Zhou, Ying Ma*, Run-Ling Wang*. Design, synthesis, biological evaluation and molecular dynamics of LAR inhibitors. [J]. Computational Biology and Chemistry. 2021; 92, 107481. Doi: 10.1016/j.compbiolchem.2021.107481.

  5. Liang Zhou, Yong Feng, Yang-Chun Ma, Zhao Zhang, Jing-Wei Wu, Shan Du, Wei-Ya Li, Xin-Hua Lu, Ying Ma*, Run-Ling Wang*. Exploring the mechanism of the potent allosteric inhibitor compound2 on SHP2WT and SHP2F285S by molecular dynamics study. [J]. Journal of Molecular Graphics and Modelling. 2021; 103, 107807. Doi: 10.1016/j.jmgm.2020.107807.

  6. Wen-Shan Liu, Bing Yang, Rui-Rui Wang, Wei-Ya Li, Yang-Chun Ma, Liang Zhou ,Shan Du, Ying Ma*, Run-Ling Wang*. Design, synthesis and biological evaluation of pyridine derivatives as selective SHP2 inhibitors. [J]. Bioorganic Chemistry. 2020; 100, 103875. Doi: 10.1016/j.bioorg.2020.103875.

  7. Wei-Ya Li, Ying Ma*, Hao-Xin Li, Xin-Hua Lu, Shan Du, Yang-Chun Ma, Liang Zhou, Run-Ling Wang*. Scaffold-based selective SHP2 inhibitors design using core hopping, molecular docking, biological evaluation and molecular simulation. [J]. Bioorganic Chemistry. 2020; 105, 104391. Doi: 10.1016/j.bioorg.2020.104391.

  8. Jingwei Wu, Weiya Li, Zhihui Zheng, Xinhua Lu, Huan Zhang, Ying Ma* and Runling Wang*. Design, synthesis, biological evaluation, common feature pharmacophore model and molecular dynamics simulation studies of ethyl 4-(phenoxymethyl)-2-phenylthiazole-5-carboxylate as Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors. [J]. Journal of biomolecular structure & dynamics. 2020; 39(4): 1174-1188. Doi: 10.1080/07391102.2020.1726817.

  9. Jing-Wei Wu, Huan Zhang, Wei-Ya Lia, Xue Tang, Hong-Lian Li, Xin-Hua Lu, Zhi-Hui Zheng, Ying Ma* and Run-Ling Wang*. Design potential selective inhibitors for human leukocyte common antigen-related (PTP-LAR) with fragment replace approach. [J]. Journal of biomolecular structure & dynamics. 2020; 38(18): 5338-5348. Doi: 10.1080/07391102.2019.1699862.

  10. Liang Zhou, Yong Feng, Yang-Chun Ma, Zhao Zhang, Jing-Wei Wu, Shan Du,Wei-Ya Li, Xin-Hua Lu, Ying Ma*, Run-Ling Wang*. Exploring the mechanism of the potent allosteric inhibitor compound2 on SHP2WT and SHP2F285S by molecular dynamics study, [J]. Journal of molecular graphics & modelling. 2020; 103 107807. Doi: 10.1016/j.jmgm.2020.107807.

  11. Jingwei Wu, Yangchun Ma, Hui Zhou, Liang Zhou, Shan Du, Yingzhan Sun, Weiya Li, Weili Dong*, Runling Wang*. Identification of protein tyrosine phosphatase 1B (PTP1B) inhibitors through De Novo Evoluton, synthesis, biological evaluation and molecular dynamics simulation. [J]. Biochemical and biophysical research communications. 2020; 526(1): 273-280. Doi: 10.1016/j.bbrc.2020.03.075.

  12. Jingwei Wu, Huan Zhang, Guilong Zhao*, and Runling Wang*. Allosteric inhibitors of SHP2: an updated patent review (2015-2020). [J]. Current Medicinal Chemistry. 2020; 28(19). Doi: 10.2174/1568011817666200928114851.

  13. Wen-Shan Liu, Wen-Yan Jin, Liang Zhou, Xing-Hua Lu, Wei-Ya Li, Ying Ma* & Run-Ling Wang*. Structure based design of selective SHP2 inhibitors by De novo design, synthesis and biological evaluation. [J]. Journal of Computer-Aided Molecular Design. 2019; 33(8):759-774. Doi: 10.1007/s10822-019-00213-z.

  14. Wen-Shan Liu, Rui-Rui Wang, Ying-Zhan Sun, Wei-Ya Li, Hong-Lian Li, Chi-Lu Liu, Ying Ma*, Run-Ling Wang*. Exploring the effect of inhibitor AKB-9778 on VE-PTP by molecular docking and molecular dynamics simulation. [J]. Journal of Cellular Biochemistry. 2019; 120(10): 17015-17029. Doi: 10.1002/jcb.28963.

  15. Li Wei-Ya, Duan Yu-Qing, Ma Yang-Chun, Lu Xin-Hua, Ma Ying*, Run-Ling Wang*. Exploring the cause of the inhibitor 4AX attaching to binding site disrupting protein tyrosine phosphatase 4A1 trimerization by molecular dynamic simulation. [J]. Journal of Biomolecular Structure & Dynamics. 2019; 37(18): 4840-4851. Doi: 10.1080/07391102.2019.1567392.

  16. Yang-Chun Ma, Bing Yang, Xin Wang, Liang Zhou, Wei-Ya Li, Wen-Shan Liu, Xin-Hua Lu, Zhi-Hui Zheng, Ying Ma*, Run-Ling Wang*. Identification of novel inhibitor of protein tyrosine phosphatases delta: structure-based pharmacophore modeling, virtual screening, flexible docking, molecular dynamics simulation, and post-molecular dynamics analysis. [J]. J Biomol Struct Dyn. 2019; 38(15): 4432-4448. Doi: 10.1080/07391102.2019.1682050.

  17. Shan Du, Bing Yang, Xin Wang, Wei-Ya Li, Xin-Hua Lu, Zhi-Hui Zheng, Ying Ma*, Run-Ling Wang*. Identification of potential leukocyte antigen-related protein (PTP-LAR) inhibitors through 3D QSAR pharmacophore-based virtual screening and molecular dynamics simulation. [J]. J Biomol Struct Dyn. 2019; 38(14): 4232-4245. Doi: 10.1080/07391102.2019.1676825.

  18. Wen-Shan Liu, Rui-Rui Wang, Hai Yue, Zhi-Hui Zheng, Xin-Hua Lu, Shu-Qing Wang, Wei-Li Dong*, Run-Ling Wang*. Design, synthesis, biological evaluation and molecular dynamics studies of 4-thiazolinone derivatives as Protein tyrosine phosphatase 1B (PTP1B) inhibitors. [J]. J Biomol Struct Dyn. 2019; 38(13): 3814-3824. Doi:10.1080/07391102.2019.1664333.

  19. Wen-Shan Liu, Rui-Rui Wang, Wei-Ya Li, Mei Rong, Chi-Lu Liu, Ying Ma*, Run-Ling Wang*. Investigating the reason for loss-of-function of Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) caused by Y279C mutation through molecular dynamics simulation. [J]. J Biomol Struct Dyn. 2019; 38(9): 2509-2520. Doi: 10.1080/07391102.2019.1634641.

  20. Rui-Rui Wang, Wen-Shan Liu, Liang Zhou, Ying Ma*, Run-Ling Wang*. Probing the acting mode and advantages of RMC-4550 as an Src-homology 2 domain containing protein tyrosine phosphatase (SHP2) inhibitor at molecular Level through molecular docking and molecular dynamics. [J]. J Biomol Struct Dyn. 2019; 38(5): 1525-1538. Doi: 10.1080/07391102.2019.1613266.

  21. Rui-Rui Wang, Ying Ma, Shan Du, Wei-Ya Li, Ying-Zhan Sun, Hui Zhou, Run-Ling Wang*. Exploring the reason for increased activity of SHP2 caused by D61Ymutation through molecular dynamics. [J]. Computational Biology and Chemistry. 2019; 78: 133-143. Doi: 10.1016/j.compbiolchem.2018.10.013.

  22. Ying-Zhan Sun, Jing-Wei Wu, Xin-Hua Lu, Ying Ma*, Run-Ling Wang*. Exploring the effect of aplidin on low molecular weight protein tyrosine phosphatase by molecular docking and molecular dynamic simulation study. [J]. Computational Biology and Chemistry. 2019; 83: 107123. Doi: 10.1016/j.compbiolchem.2019.107123.

  23. Jing-Wei Wu, Ling Yin, Yu-Qiang Liu, Huan Zhang, Ya-Fei Xie, Run-Ling Wang*, Gui-Long Zhao*. Synthesis, biological evaluation and 3D-QSAR studies of 1,2,4-triazole-5-substituted carboxylic acid bioisosteres as uric acid transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia associated with gout. [J]. Bioorganic & Medicinal Chemistry Letters，2019; 29(3): 383-388. Doi: 10.1016/j.bmcl.2018.12.036.

  24. Jingwei Wu, Yingzhan Sun, Hui Zhou, Ying Ma*, Runling Wang*. Design, synthesis, biological evaluation and molecular dynamics simulation studies of (R)-5-methylthiazolidin-4-One derivatives as megakaryocyte protein tyrosine phosphatase 2 (PTP-MEG2) inhibitors for the treatment of type 2 diabetes. [J]. Journal of Biomolecular Structure & Dynamics. 2019; 38(11): 3156-3165. Doi: 10.1080/07391102.2019.1654410.

  25. Liang Zhou, Yang-Chun Ma, Xue Tang, Wei-Ya Li, Ying Ma* & Run-Ling Wang*, Identification of the potential dual inhibitor of protein tyrosine phosphatase sigma and leukocyte common antigen-related phosphatase by virtual screen, molecular dynamic simulations and postanalysis. [J]. Journal of Biomolecular Structure & Dynamics. 2019; 39(1): 45-62. Doi: 10.1080/07391102.2019.1705913.

  26. Chen Li，Tan Xiao-li，ANTAL Rockenbauer，Wang Run-ling*，Liu Yang-ping*. Efficient Synthesis and Characterization of PEGylated/Deuterated Derivatives of Monophosphonated Tetrathiatriarylmethyl Radicals, [J]. Chinese Journal of Magnetic Resonance. 2019; 36(2): 208-218


 

Grant

Ongoing:

Design, synthesis and activity of selective inhibitors of SHP2 mutants E76K and D61G associated with Juvenile myelomonocytic leukemia. NSFC (81773569), 2018.01- 2021.12, PI.


Completed:

1. Design, synthesis and activity screening of anti-leukemia drugs targeting SHP2. Project supported by the Funds for International Cooperation and Exchange of the National Natural Science Foundation of China (81611130090), 2016.1.1-2018.12.31, PI.

2. The development of new type of ibuprofen targeted transdermal preparations. Tianjin Double Five Science & Technology Fund Planning Project (SW20080005), 2008/12-2011/12, PI.

3. The research based on the structure of PTP1B enzyme to discover lead antidiabetic drugs. Key project of Tianjin Natural Science Foundation (09JCZDJC21600), 2009/04-2012/03, PI.

4. The design, synthesis, and biological study of antidiabetic drugs targeting PTP-1B, PPAR-α and PPAR-γ. NSFC (20972112), 2010/01-2012/12, PI.

5. The design, synthesis, and biological study of antidiabetic drugs targeting PTP-1B, PPAR-α and PPAR-γ. The Specialized Research Fund for the Doctoral Program of Higher Education of China (20091202110010), 2010/01-2012/12, PI.

6. The research on the selective protein tyrosine phosphatase SHP2 inhibitors. NSFC (81273361), 2013/01-2016/12, PI.